Taipei City – January 7, 2025
Dr. Lee, renowned for her expertise in treating hair loss, was specially invited to lead this trial due to her exceptional professional background and achievements. A graduate of Taipei Medical University with advanced training at Harvard University, Dr. Lee previously served as Director of the Medical Aesthetics and Cosmetics Research Center at Taipei Medical University, where her contributions to the field were widely recognized.
Dr. Lee, renowned for her expertise in treating hair loss, was specially invited to lead this trial due to her exceptional professional background and achievements. A graduate of Taipei Medical University with advanced training at Harvard University, Dr. Lee previously served as Director of the Medical Aesthetics and Cosmetics Research Center at Taipei Medical University, where her contributions to the field were widely recognized.
The trial is a collaborative endeavor with Taipei Medical University and is conducted at Shuang-Ho Hospital, part of the university’s healthcare network. It focuses on the application of OMNIHAIR’s core ingredients in promoting hair growth, targeting common hair loss conditions such as alopecia areata, androgenetic alopecia, and stress-induced hair loss. This collaboration aims to achieve a groundbreaking advancement in hair restoration technologies.
OMNIHAIR incorporates patented extraction technology developed by 3D Global Biotech Inc., utilizing a proprietary method to extract follicular mesenchymal stem cell exosomes and growth factors. This exclusive ingredient, specifically designed for individuals experiencing baldness, thinning hair, and reduced hair density, has undergone rigorous safety certification by SGS in compliance with international OECD standards for cosmetic ingredients. The ingredient has also earned International Nomenclature Cosmetic Ingredient (INCI) accreditation, with research findings published in prestigious international journals. These validations underscore its scientific robustness and application potential as a safe and effective solution for hair health.
Under the leadership of Dr. Woan-Ruoh Lee, the clinical trial is conducted by a professional dermatology team at Shuang-Ho Hospital, adhering strictly to established regulations and ethical guidelines for human studies. This ensures the accuracy of data and credibility of the research outcomes. By combining follicular mesenchymal stem cell exosomes and growth factors, OMNIHAIR aims to fundamentally improve follicular health, offering a targeted solution for baldness and thinning hair.
The launch of this clinical application trial represents a pivotal milestone for OMNIHAIR as it progresses toward commercialization. It also introduces exciting new possibilities for advancements in hair restoration technology. YC Biotech Co., Ltd. remains committed to closely monitoring the trial’s progress and advancing hair care technology, striving to deliver innovative and effective solutions for patients.
YC Biotech Co., Ltd. is dedicated to the research and development of high-end biotech products and clinical applications. By leveraging cutting-edge technology, the company seeks to enhance patients’ quality of life while exploring new possibilities in the biotech field. Through continuous innovation, YC Biotech aims to provide superior medical-grade solutions to consumers worldwide.